Results from a controlled, randomised trial in UK concluded that concomitant vaccination with one of two SARS-CoV-2 vaccines (ChAdOx1 or BNT162b2) plus an age-appropriate influenza vaccine raised no safety concerns and preserved antibody responses to both vaccines.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext
Available vaccines in Europe
Vaccine composition
On 24 September 2021, WHO published recommendations for the components of influenza vaccines for use in the 2022 southern hemisphere influenza season:
Egg-based Vaccines
-
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
-
an A/Darwin/9/2021 (H3N2)-like virus;
-
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
-
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
-
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
-
an A/Darwin/6/2021 (H3N2)-like virus;
-
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
-
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
-
It is recommended that trivalent influenza vaccines for use in the 2022 southern hemisphere influenza season contain the following:
Egg-based vaccines
-
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
-
an A/Darwin/9/2021 (H3N2)-like virus; and
-
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell- or Recombinant-based vaccines
-
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
-
an A/Darwin/6/2021 (H3N2)-like virus; and
-
a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
The full report is published here.
On 26 February 2021, WHO published recommendations for the components of influenza vaccines for use in the 2021-2022 northern hemisphere influenza season:
Egg-based Vaccines
-
an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
-
an A/Cambodia/e0826360/2020 (H3N2)-like virus;
-
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
-
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
-
an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
-
an A/Cambodia/e0826360/2020 (H3N2)-like virus;
-
a B/Washington/02/2019 (B/Victoria lineage)-like virus; and
-
a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It was recommended that the influenza B virus component of both trivalent vaccine types for use in the 2021–2022 northern hemisphere influenza season should be a B/Washington/02/2019-like virus of the B/Victoria-lineage.